CDKN2A(Cyclin-Dependent Kinase Inhibitor 2A)是一个重要的抑癌基因,属于INK4(Inhibitor of CDK4)基因家族。该基因编码两种蛋白质:p16INK4a和p14ARF(在人类中为p16INK4a和p19ARF在小鼠中),它们通过不同的机制调控细胞周期和抑制肿瘤发生。p16INK4a通过抑制CDK4/6-cyclin D复合物来阻止Rb蛋白的磷酸化,从而阻断细胞从G1期进入S期,抑制细胞增殖。p14ARF则通过稳定p53蛋白来诱导细胞周期停滞或凋亡,从而防止异常细胞生长。CDKN2A基因的突变或缺失与多种癌症密切相关,包括黑色素瘤、胰腺癌、肺癌和头颈部肿瘤等。突变可能导致p16INK4a或p14ARF功能丧失,使细胞周期失控,促进肿瘤发展。CDKN2A的过表达通常与细胞衰老相关,可能作为抗肿瘤机制的一部分,而表达降低则可能导致细胞增殖失控和癌症风险增加。该基因家族(INK4)的共性是通过抑制CDK(细胞周期蛋白依赖性激酶)来调控细胞周期,成员还包括CDKN2B(p15INK4b)、CDKN2C(p18INK4c)和CDKN2D(p19INK4d)。CDKN2A的表达受表观遗传调控(如甲基化)和转录因子(如E2F)的影响。此外,CDKN2A的遗传变异(如某些SNPs)可能增加个体对特定癌症的易感性。研究CDKN2A有助于开发针对细胞周期调控的癌症治疗方法,例如CDK4/6抑制剂(如帕博西尼)已用于某些癌症治疗。
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
None
CDKN2A基因(以及对应的蛋白质)的细胞分布位置:
CDKN2A基因的本体(GO)信息:
名称 |
---|
4110 Cell cycle [PATH:hsa04110] |
4115 p53 signaling pathway [PATH:hsa04115] |
5200 Pathways in cancer [PATH:hsa05200] |
5206 MicroRNAs in cancer [PATH:hsa05206] |
5203 Viral carcinogenesis [PATH:hsa05203] |
5212 Pancreatic cancer [PATH:hsa05212] |
5214 Glioma [PATH:hsa05214] |
5220 Chronic myeloid leukemia [PATH:hsa05220] |
5218 Melanoma [PATH:hsa05218] |
5219 Bladder cancer [PATH:hsa05219] |
5223 Non-small cell lung cancer [PATH:hsa05223] |
5166 HTLV-I infection [PATH:hsa05166] |
名称 |
---|
Cell Cycle |
Cell Cycle, Mitotic |
Cellular responses to stress |
Cellular Senescence |
Cyclin D associated events in G1 |
G1 Phase |
Metabolism of proteins |
Mitotic G1-G1/S phases |
Oncogene Induced Senescence |
Oxidative Stress Induced Senescence |
Post-translational protein modification |
Senescence-Associated Secretory Phenotype (SASP) |
SUMO E3 ligases SUMOylate target proteins |
SUMOylation |
SUMOylation of DNA damage response and repair proteins |
疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
Melanoma astrocytoma syndrome | 0.360542884 | 2 | 0 | BeFree_CLINVAR_CTD_human_ORPHANET |
melanoma | 0.36 | 508 | 13 | BeFree_CTD_human_GAD_LHGDN |
MELANOMA-PANCREATIC CANCER SYNDROME | 0.36 | 1 | 2 | CLINVAR_CTD_human_UNIPROT |
Precursor Cell Lymphoblastic Leukemia Lymphoma | 0.274751948 | 56 | 1 | BeFree_CTD_human_GAD_GWASCAT_LHGDN |
Liver carcinoma | 0.251944713 | 95 | 0 | BeFree_CTD_human_LHGDN_RGD |
Lung Neoplasms | 0.244655508 | 39 | 0 | BeFree_CTD_human_LHGDN_RGD |
MELANOMA, CUTANEOUS MALIGNANT, 2 | 0.24 | 10 | 1 | CTD_human_UNIPROT |
LI-FRAUMENI SYNDROME 1 | 0.24 | 1 | 0 | CTD_human_UNIPROT |
Esophageal Neoplasms | 0.221898372 | 25 | 0 | BeFree_CTD_human_GAD_LHGDN_RGD |
Mesothelioma | 0.219854983 | 38 | 0 | BeFree_CTD_human_LHGDN_RGD |
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话: 0531-88819269
E-mail: product@genelibs.com
关注微信订阅号,实时查看信息,关注医学生物学动态。